Tracey Schroeder Swartz, OD
Optometrist · Huntsville, ALNPI 1306973417
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $44,644 of the $69,252 with a category attached, or 64.5%. Glaukos Corporation accounts for 75.3% of it on its own, with 22 other manufacturers making up the rest. Among optometrist clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 429 payments — averaging $161.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$52K
- AbbVie$8K
- Sun Pharmaceutical Industries Inc.$2K
- Johnson & Johnson Surgical Vision, Inc.$1K
- Bausch & Lomb Americas Inc.$1K
- Tarsus Pharmaceuticals, Inc.$923
- plus $4K from 17 others
What the payments were for
- Consulting fees$44,64464%
- Speaking & faculty fees$4,6577%
- Travel & lodging$7,42211%
- Food & beverage$12,51518%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 58 | $52,160 |
| AbbVie(2 entities) | 112 | $8,090 |
| Sun Pharmaceutical Industries Inc. | 99 | $1,974 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $1,044 |
| Bausch & Lomb Americas Inc. | 31 | $1,039 |
| Tarsus Pharmaceuticals, Inc. | 29 | $923 |
| Oyster Point Pharma, Inc. | 22 | $619 |
| Alcon | 13 | $616 |
| Novartis | 14 | $465 |
| Biotissue Holdings Inc. | 11 | $459 |
| Shire North American Group Inc | 7 | $395 |
| Harrow Eye, LLC | 8 | $311 |
| Johnson & Johnson Vision Care, Inc. | 2 | $241 |
| Dompe US, Inc. | 6 | $238 |
| Amgen | 3 | $157 |
| Sight Sciences, Inc. | 3 | $154 |
| Astellas Pharma US Inc | 1 | $134 |
| Carl Zeiss Meditec, Inc. | 1 | $105 |
| Kala Pharmaceuticals, Inc. | 2 | $39 |
| Staar Surgical Company | 1 | $29 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $24 |
| Aerie Pharmaceuticals, Inc. | 1 | $19 |
| Thea Pharma Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KXL System$29,287
- CE-marked KXLA system$14,831
- VUITY$4,767
- Tecnis Symfony IOL$1,000
- XIIDRA$625
- MIEBO$486
- LUMIGAN$353
- CEQUA$333
- XDEMVY$246
- Acuvue$241
- AcrySof IQ VIVITY$137
- iDose$125
- Oxervate$125
- VYZULTA$123
- VEVYE$122
- Photrexa Viscous and Photrexa$119
- DURYSTA$118
- iStent Trabecular Micro-Bypass System Model iS3$113
- TEPEZZA$110
- TYRVAYA$110
How this compares
$69,252 in reported general payments places this provider in the 95th percentile of 749 optometrist providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XdemvyLotilaner | 87 | $163,443 |
| XiidraLifitegrast | 58 | $77,565 |
| RestasisCyclosporine | 35 | $41,382 |
| MieboPerfluorohexyloctane/Pf | 47 | $34,697 |
| LumiganBimatoprost | 53 | $29,107 |
| Loteprednol Etabonate | 143 | $26,793 |
| CequaCyclosporine | 19 | $20,749 |
| Cyclosporine | 21 | $11,617 |
| Fluorometholone | 57 | $4,687 |
| Doxycycline Monohydrate | 175 | $4,555 |
| Latanoprost | 171 | $3,430 |
| Ketorolac Tromethamine | 26 | $1,814 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 80 | $1,795 |
| Prednisolone Acetate | 36 | $1,644 |
| Travoprost | 11 | $1,209 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Tarsus Pharmaceuticals, Inc.Xdemvy | $923 | $163,44387 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $1,039 | $112,261105 claims |
| AbbVieRestasis, Lumigan | $8,090 | $70,48888 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $24 | $26,793143 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $1,974 | $20,74919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 749 optometrist providers in Alabama.
Other optometrist in Huntsville
- Neena JamesHuntsville$74K
- Patricia FulmerHuntsville$45K
- Mohammed HaqueHuntsville$10K
- Benjamin PendergrassHuntsville$9K
- Kristin SullinsHuntsville$7K
- Jessica BoydHuntsville$6K
- Alan PeasleeHuntsville$6K
- Kenneth MoultrieHuntsville$5K
- Mark SchaefferHoover$470K
- Kelly NicholsBirmingham$231K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.